
ALT Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) has reached agreement with the FDA on the design of its registrational Phase 3 trial of REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). That clears a key regulatory step ahead of a planned start in the second half of 2027. The agreement gives the PRISM Pharmaceuticals Index company a defined path toward what could become the first approved drug for a rare inherited disease that has no approved pharmacologic therapy.

ALT Red Cat Pulls 2026 Revenue Target as Q3 Sales Miss; Shares Slide Premarket Red Cat Holdings, Inc. (NASDAQ: RCAT) withdrew its full-year 2026 revenue target on Monday after third-quarter revenue came in far below Wall Street’s forecast. Revenue rose 22% from a year earlier to $11.8 million, but analysts had expected about $39.5 million. As a result, shares of the PRISM Aerospace and Defense Index member fell about 25% in premarket trading Tuesday.





